KR100834138B1 - 카할라리드 에프 - Google Patents

카할라리드 에프 Download PDF

Info

Publication number
KR100834138B1
KR100834138B1 KR1020037005347A KR20037005347A KR100834138B1 KR 100834138 B1 KR100834138 B1 KR 100834138B1 KR 1020037005347 A KR1020037005347 A KR 1020037005347A KR 20037005347 A KR20037005347 A KR 20037005347A KR 100834138 B1 KR100834138 B1 KR 100834138B1
Authority
KR
South Korea
Prior art keywords
cancer
reconstituted liquid
kahalarid
reconstituted
liquid according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020037005347A
Other languages
English (en)
Korean (ko)
Other versions
KR20030044005A (ko
Inventor
페어클로스글린토마스
누엔바스티안
웨이트만스티브
Original Assignee
파르마 마르, 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 파르마 마르, 에스.에이. filed Critical 파르마 마르, 에스.에이.
Publication of KR20030044005A publication Critical patent/KR20030044005A/ko
Application granted granted Critical
Publication of KR100834138B1 publication Critical patent/KR100834138B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Carbon And Carbon Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020037005347A 2000-10-31 2001-10-31 카할라리드 에프 Expired - Fee Related KR100834138B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US24447100P 2000-10-31 2000-10-31
US60/244,471 2000-10-31
US24622900P 2000-11-06 2000-11-06
US60/246,229 2000-11-06
US34844901P 2001-10-19 2001-10-19
US60/348,449 2001-10-19
PCT/GB2001/004821 WO2002036145A2 (en) 2000-10-31 2001-10-31 Kahalalide f formulation

Publications (2)

Publication Number Publication Date
KR20030044005A KR20030044005A (ko) 2003-06-02
KR100834138B1 true KR100834138B1 (ko) 2008-06-02

Family

ID=27399760

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020037005347A Expired - Fee Related KR100834138B1 (ko) 2000-10-31 2001-10-31 카할라리드 에프

Country Status (22)

Country Link
US (1) US7473681B2 (https=)
EP (1) EP1330258B1 (https=)
JP (2) JP2004512370A (https=)
KR (1) KR100834138B1 (https=)
CN (1) CN1568192A (https=)
AT (1) ATE314084T1 (https=)
AU (2) AU1074902A (https=)
BR (1) BR0114912A (https=)
CA (1) CA2425627A1 (https=)
CY (1) CY1105009T1 (https=)
CZ (1) CZ20031211A3 (https=)
DE (1) DE60116359T2 (https=)
DK (1) DK1330258T3 (https=)
ES (1) ES2256305T3 (https=)
HK (1) HK1054192B (https=)
HU (1) HUP0600031A3 (https=)
IL (2) IL155297A0 (https=)
MX (1) MXPA03003704A (https=)
NO (1) NO331082B1 (https=)
NZ (1) NZ525243A (https=)
SK (1) SK286421B6 (https=)
WO (1) WO2002036145A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0002952D0 (en) * 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
US20050054555A1 (en) * 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy
WO2003033012A1 (en) * 2001-10-19 2003-04-24 Pharma Mar, S.A. Kahalalide compounds for use in cancer therapy
GB0304367D0 (en) * 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
DK1572726T3 (da) * 2002-10-18 2011-03-28 Pharma Mar Sau 4-methylhexansyre-kahalalid F-forbindelse
NZ539093A (en) * 2002-10-18 2007-10-26 Pharma Mar Sau 4-methylhexanoic kahalaide F compound
US7507708B2 (en) 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
DE10329847A1 (de) * 2003-07-02 2005-01-20 Toximed Gmbh Pharmazeutischer Wirkstoff gegen Prostatakarzinome
GB0321066D0 (en) * 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
GB0408958D0 (en) * 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds
DK1827500T3 (da) * 2004-10-26 2009-08-31 Pharma Mar Sa Pegyleret liposomal doxorubicin i kombination med ecteinescidin 743
RS50510B (sr) 2004-10-29 2010-03-02 Pharma Mar S.A., Sociedad Unipersonal Formulacije koje sadrže ekteinascidin i disaharid
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
WO2009052379A2 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Improved antitumoral treatments
AU2009209541A1 (en) * 2008-01-30 2009-08-06 Pharma Mar, S.A. Improved antitumoral treatments
CN101965192A (zh) * 2008-03-07 2011-02-02 法马马有限公司 改善的抗肿瘤治疗
WO2009135939A2 (en) * 2008-05-09 2009-11-12 Pharma Mar, S.A. Depsipeptide for use in cancer therapy
HRP20231233T1 (hr) 2017-04-27 2024-01-19 Pharma Mar, S.A. Antitumorski spojevi

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0610078B1 (en) 1993-02-03 1997-04-16 Pharma Mar, S.A. Cytotoxic and antiviral compound

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
JP2799483B2 (ja) 1988-03-09 1998-09-17 大塚製薬株式会社 インターロイキン−１β組成物の安定化方法
GB8819607D0 (en) 1988-08-17 1988-09-21 Wellcome Found Novel combination
IE64738B1 (en) 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
JP2971680B2 (ja) 1991-10-02 1999-11-08 山之内製薬株式会社 組織プラスミノーゲン活性化因子含有組成物
JPH0597703A (ja) 1991-10-04 1993-04-20 Yamanouchi Pharmaceut Co Ltd 改変型組織プラスミノーゲン活性化因子含有組成物
US5550124A (en) 1991-12-10 1996-08-27 University Of Southern California Use of peripheral-type benzodiazpine sites for treatment of CNS trauma or disease
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US6274551B1 (en) * 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
JP3927248B2 (ja) * 1995-07-11 2007-06-06 第一製薬株式会社 Ｈｇｆ凍結乾燥製剤
GB9601120D0 (en) 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
JPH1014581A (ja) 1996-07-08 1998-01-20 Morinaga Milk Ind Co Ltd ウサギ型マクロファージ・コロニー刺激因子及びこれをコードするｄｎａ断片
DE69719265T2 (de) 1996-09-06 2003-12-04 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute, Kumamoto Medizinische Zusammensetzung die Gewebeplasminogenaktivator und Nikotinamid enthält
JP4025394B2 (ja) * 1996-09-06 2007-12-19 財団法人化学及血清療法研究所 組織プラスミノーゲン活性化因子医薬組成物
GB9803448D0 (en) * 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
GB9807639D0 (en) 1998-04-14 1998-06-10 Kennedy Rheumatology Inst Anti-inflammatory agents
CN1322136A (zh) 1998-09-23 2001-11-14 马库斯·基普 用于选择性神经元辐射防护的神经亲免素类物质
GB0002952D0 (en) 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
US20050054555A1 (en) 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0610078B1 (en) 1993-02-03 1997-04-16 Pharma Mar, S.A. Cytotoxic and antiviral compound

Also Published As

Publication number Publication date
EP1330258B1 (en) 2005-12-28
AU2002210749B2 (en) 2006-12-21
CN1568192A (zh) 2005-01-19
HUP0600031A3 (en) 2012-02-28
DE60116359D1 (de) 2006-02-02
JP2004512370A (ja) 2004-04-22
CZ20031211A3 (cs) 2003-09-17
KR20030044005A (ko) 2003-06-02
IL155297A0 (en) 2003-11-23
JP2010047601A (ja) 2010-03-04
PL360848A1 (en) 2004-09-20
MXPA03003704A (es) 2004-05-04
ATE314084T1 (de) 2006-01-15
US7473681B2 (en) 2009-01-06
CY1105009T1 (el) 2010-03-03
DE60116359T2 (de) 2006-09-28
AU1074902A (en) 2002-05-15
HK1054192A1 (en) 2003-11-21
SK5022003A3 (en) 2003-12-02
BR0114912A (pt) 2003-10-14
WO2002036145A2 (en) 2002-05-10
NO331082B1 (no) 2011-10-03
HK1054192B (en) 2006-09-08
NZ525243A (en) 2005-01-28
WO2002036145A3 (en) 2002-10-17
CA2425627A1 (en) 2002-05-10
SK286421B6 (sk) 2008-09-05
DK1330258T3 (da) 2006-05-22
NO20031860D0 (no) 2003-04-25
US20040067895A1 (en) 2004-04-08
IL155297A (en) 2010-05-31
ES2256305T3 (es) 2006-07-16
HUP0600031A2 (en) 2006-05-29
EP1330258A2 (en) 2003-07-30
WO2002036145A8 (en) 2003-10-23
NO20031860L (no) 2003-06-30

Similar Documents

Publication Publication Date Title
KR100834138B1 (ko) 카할라리드 에프
US12268783B2 (en) Platform drug delivery system utilizing crystal engineering and theanine dissolution
JP2004512370A5 (https=)
AU2002210749A1 (en) Kahalalide F formulation
US20090298752A1 (en) Aplidine treatment of cancers
JP2009519250A (ja) リポソーム組成物
US20050054555A1 (en) Kahalalide compounds for use in cancer therapy
AU2002334203C1 (en) Kahalalide compounds for use in cancer therapy
RU2292216C2 (ru) Кахалалид f
AU2002334203A1 (en) Kahalalide compounds for use in cancer therapy
MXPA03003230A (es) Tratamiento de canceres.
NZ525196A (en) Treatment of cancers by aplidine in conjunction with a myoprotector
PL203676B1 (pl) Liofilizowany preparat kahalalidu F, zestaw, odtworzony roztwór i zastosowanie
WO2019211829A1 (en) Compositions and methods for treating glioblastoma
KR20060088569A (ko) 암 억제 활동을 하는 재조합 단백질, 그 암호화 유전자 및사용
MXPA04003672A (es) Compuestos de kahalalida para uso en terapia de cancer.

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20110516

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20120527

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20120527